
TCGX (TCGX) to Combine with TriGemX Bio in $403M Deal
TCGX I (NASDAQ:TCGX) has signed a definitive agreement to combine with drug developer TriGemX Bio at a pro forma enterprise value of $402.8 million. New York-based TriGemX Bio is developing a drug candidate for the treatment of acute migraines that is currently in Phase III trials. More
Nicholas Alan Clayton·Oct 19








